Martín-del Campo M, Fernández-Martínez RF, Moreno-Coutiño G, Arenas R

Language: Spanish
References: 13
Page: 534-537
PDF size: 415.08 Kb.

ABSTRACT

Background: Skin disorders are commonly seen during the course of HIV infection. Onychomycosis is four times more common in the immunosuppressed population and its frequency is 46-80%.
Objective: To describe the cases of onychomycosis in patients with HIV with or without prophylactic treatment with fluconazole.
Material and method: A descriptive, observational, prospective and transversal study of patients with HIV referred to the dermatology service of Medical Center ISSEMyM Ecatepec, Mexico. A nail-scraping sample from toenails was taken from every patient, with or without clinical appearance of onychomycosis. Recorded data were: age, gender, time of HIV diagnosis, CD4 lymphocyte count, viral load, if they were receiving prophylactic oral fluconazole, clinical presentation of onychomycosis and mycological study including KOH and culture.
Results: Twenty-nine patients were included. Fifteen cases were diagnosed with onychomycosis. The most common clinical presentation was total dystrophic onychomycosis. Seven cultures were positive, and the most common fungal agent was Trichophyton rubrum. Of these patients with onychomycosis, 7 were receiving prophylactic fluconazole for immunosuppression, and of these, 2 had total dystrophic onychomycosis and 5 subungueal distal and lateral onychomycosis.
Conclusion: Oral fluconazole is prescribed by a different indication than onychomycosis, this mycosis can be reduced during prophylaxis, but it is not enough to eliminate the etiological agent.

REFERENCES

1. Creed R, Morrison LK, Ravanfar P, Mendoza N, Tyring S. Skin complications of HIV infection. Expert Rev Dermatol 2009;5:509-521.

2. Calle J, Cardona N. Micosis más prevalentes en paciente con VIH/SIDA, correlación con el estado inmunológico del huésped. Rev Asoc Colomb Dermatol 2006;17:211-220.

3. Rugeles MJ, Vasquez L. Etiología y características clínicas de la onicomicosis en un grupo de pacientes inmunosuprimidos. Infec Tro 2001;5:7-13.

4. Larruskian J, Idigoras P, Mendiola J. Onicomicosis: diagnóstico y tratamiento. Inf Ter Salud 2008;32:83-92.

5. Cavallera E, Asbati M. Onicomicosis por hongos filamentosos no dermatofitos. Dermatología Venezolana 2006;44:4-10.

6. Khambaty MM, Hsu SS. Dermatology of the patients with HIV. Emerg Med Clin N Am 2010;28:355-368.

7. Arenas R, Aristimuño M, Abiega C, Vick R. La infección por el virus de inmunodeficiencia humana y onicomicosis. Dermatología venezolana1999;37:28-29.

8. Arenas R. Dermatofitosis en México. Rev Iberoam Micol 2002;19:63-67.

9. Scher Ret AL. Onycomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56:939-944.

10. De Magalhaes K, Machado CM, Fonseca II, Carvalhaes J, Delgado M, Sette de Melo R. Hongos filamentosos no dermatofitos: onicomicosis en cuatro pacientes infectados con el virus de la inmunodeficiencia humana.Rev Iberoam Micol 2008;25:45-49.

11. Singal A, Khanna D. Onychomycosis: Diagnosis and management. Indian J Dermatol Venereol Leprol 2011;77:659-672.

12. Aberg J, Powderly W. HIV: primary and secondary prophylaxis for opportunistic infections. Clin Evid (Online) 2010;28:0908.

13. Tabolli S, Alessandroni L, Gaido J, Sampogna F, et al. Health-related quality of life and nail disorders. Acta Derm Venereol 2007;87:255-259.